{
    "nctId": "NCT06274515",
    "briefTitle": "A Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies",
    "officialTitle": "A Multi Cohort Translational Research Study to Investigate Mechanisms of Resistance to Breast Cancer Therapies",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 320,
    "primaryOutcomeMeasure": "Changes from baseline in HER2 protein levels measured at the time of disease progression/recurrence (Cohorts H1 and H2)",
    "eligibilityCriteria": "General Inclusion Criteria:\n\n* Willingness to undergo a procedure to obtain tumor tissue (e.g. biopsy) and blood draw\n* Diagnosis of HER2+, HR+ (for cohort R1) or triple negative breast cancer (for cohort T1) as per local assessment\n* Availability of an archival tumor tissue (most recent pre-treatment tumor tissue is preferred)\n* Unequivocally growing tumor lesion (progressive lesion) that is accessible for resection, excision or core needle biopsy\n* Discontinuation of prior anti-cancer treatment outlined below should not be longer than 4 weeks from participation in this study\n\nInclusion criteria for participants in the cohorts studying acquired resistance\n\n* Participant had undergone regular monitoring for disease progression as per local practice (preferably every 3-6 months) while on most recent breast cancer therapy\n* Accessible tumor lesion that newly appeared or a lesion that started to regrow while the participant was at least 6 months on therapy\n\nInclusion criteria for participants in the cohort studying primary resistance\n\n* Accessible tumor lesion that continued to increase in size or a newly appearing lesion (as confirmed by routine tumor assessment) while treated for at least 4 weeks but less than 6 months on therapy\n\nExclusion Criteria:\n\n* Any risks factors that increase the risk of complications associated with the procedure to obtain tumor tissue (e.g. bleeding disorders)\n* Any serious medical condition or abnormality in clinical laboratory tests that precludes an individual's safe participation in and completion of the study\n* Participant has started treatment with subsequent anti-cancer therapy\n* Participants whose progressive tumor lesion that is targeted for biopsy/resection is in the bone\n* Discontinuation of treatment was due to a reason other than disease progression",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}